INTRODUCTION
Alzheimer's disease (AD) is an age-related, irreversible brain disorder with a long asymptomatic induction time leading to memory loss, cognitive deficits, and behavior and personality changes. Risk factors for AD are old age, a family history of dementia, head trauma, Down's syndrome, female gender, apolipoprotein E4 isotype, and mutations in the genes for presenilin and possibly ␣ 1 -antichymotrypsin and ␣ 2 -macroglobulin. The strongest pathological markers for AD are abnormal accumulation of amyloid deposits and glial cell activation, indicative of inflammation. The principal molecular component of amyloid is A␤, a peptide of about 40 amino acids of unknown function, but many inflammation-related molecules are also present in amyloid. While much work has focused on the role of A␤ in AD etiology, the possible pro-or anti-inflammatory activities of A␤ in complex with lower abundance pro-and anti-inflammatory molecules has received less attention. The ubiquitous occurrence of inflammation in postmortem AD brain suggests that a disruption of endogenous anti-inflammatory pathways has occurred, which fosters a state of chronic inflammation. A few known interactions of A␤ with such endogenous anti-inflammatory molecules suggest how A␤ might play a role in disrupting the delicate balance been pro-and anti-inflammatory processes, and thereby be indirectly responsible for long-term neuronal damage in AD.
A␤ AND INFLAMMATION IN ALZHEIMER'S DISEASE
The Alzheimer's amyloid A␤ peptide has been at the center of Alzheimer's research since its discovery as the major component of amyloid plaques in Alzheimer's diseased brains. Subsequent genetic studies of relatively rare early onset and inherited forms of AD and the higher incidence of early-onset AD in Down's syndrome carriers, who have 2 copies of chromosome 21, which carries the A␤ gene, suggest a dosage-dependence of AD on A␤. (Tanzi et al., 1987) . However, the biological function of A␤ is still not known and its putative neurotoxic activity not completely understood. Chronic, long-term inflammation is a strong correlate of AD (Giometto et al., 1988) , but the link between this condition and A␤ has remained elusive. A general hypothesis for a self-perpetuating cycle of inflammation is that activated glial cells, which are a ubiquitous occurrence in AD (McGeer et al., 1988; Meda et al., 1995) , produce cytotoxic agents, possibly including A␤, that damage neurons over long periods of time (Siman et al., 1989) , and damaged neurons further activate proximal glial cells to perpetuate the inflammatory cycle (Rich et al., 1995; Breitner, 1996a; Aisen, 1997; McGeer et al., 1996 McGeer et al., , 1999 Akiyama et al., 2000) . It has been proposed that this chronic cycle is driven by cytokines, particularly IL-1 (Griffin et al., 1998) . Nonsteroidal anti-inflammatory drug administration has been shown to reduce the risk of develop- 
